Rezolute, Inc. (RZLT) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

39/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

54

Neutral

Sentiment

65

Bullish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Nevan Charles Elam
Listed since: Jan 14, 2013
Employees: 68

Market position

Volume: 6.5M; 3.82× average
Average volume: 1.7M; Average daily volume
Market cap: 490.13M USD
Beta: 0.62; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -6.21×
P/B (TTM): 4.53×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.01×

Financial statements

Income trends

Operating income

−79.89M USD-13.45%

Net income

−74.41M USD-8.70%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	—	—	—	—	13K USD
Gross profit	—	—	—	—	−13K USD
Research and development	61.53M USD	55.74M USD	43.81M USD	32.49M USD	14.99M USD
Selling, general, and administrative	18.37M USD	14.68M USD	12.18M USD	9.36M USD	7.91M USD
Operating expenses	79.89M USD	70.42M USD	55.99M USD	41.84M USD	22.88M USD
Interest income	5.48M USD	4.87M USD	4.21M USD	80K USD	63K USD
Interest expense	—	—	—	1.81M USD	375K USD
Depreciation and amortization	31K USD	36K USD	30K USD	13K USD	13K USD
Operating income	−79.89M USD	−70.42M USD	−55.99M USD	−41.84M USD	−22.89M USD
Net income	−74.41M USD	−68.46M USD	−51.79M USD	−41.06M USD	−20.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 36%; 4 beats, 5 misses, 2 met estimates
Average EPS surprise: -1.21%; 11 comparable reports
Latest EPS result: -0.16; Estimate -0.14 · Miss by 12.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings

Strong buy00%

Buy12100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

8 institutions

Cantor FitzgeraldmaintainOverweightSep 19, 2023

RZLT news

globenewswire.comJul 21, 2026

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a…

Read source

globenewswire.comJun 17, 2026

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenital HI and a case…

Read source

zacks.comJun 4, 2026

RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?

Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.

Read source

globenewswire.comJun 4, 2026

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a…

Read source

benzinga.comJun 2, 2026

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants enrolled so far…

Read source

globenewswire.comJun 2, 2026

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 REDWOOD…

Read source